FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect Efficacy With 99.9% of Pa

The Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that has been shown to act as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. The drug,

In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.